You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Moodys
AstraZeneca
Harvard Business School
Johnson and Johnson

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,107,900

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,107,900 protect, and when does it expire?

Patent 9,107,900 protects MULTAQ and is included in one NDA.

This patent has fifty-nine patent family members in twenty-nine countries.

Summary for Patent: 9,107,900
Title:Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of morality
Abstract: Methods of using dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality, articles of manufacture and packages related thereto.
Inventor(s): Radzik; Davide (Paris, FR), Van Eickels; Martin (Berlin, DE), Hamdani; Nacera (Colombes, FR), Gaudin; Christophe (Saint CLoud, FR)
Assignee: SANOFI (Paris, FR)
Application Number:13/847,159
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,107,900
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,107,900

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sanofi Aventis Us MULTAQ dronedarone hydrochloride TABLET;ORAL 022425-001 Jul 1, 2009 RX Yes Yes   Start Trial   Start Trial REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH STABLE NYHA CLASS III HEART FAILURE AND A HISTORY OF PAROXYSMAL OR PERSISTENT AF AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS   Start Trial
Sanofi Aventis Us MULTAQ dronedarone hydrochloride TABLET;ORAL 022425-001 Jul 1, 2009 RX Yes Yes   Start Trial   Start Trial REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH CORONARY HEART DISEASE AND A HISTORY OF PAROXYSMAL OR PERSISTENT AF AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,107,900

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France08 02127Apr 17, 2008
France08 03208Jun 10, 2008
09290095Feb 11, 2009

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Express Scripts
Baxter
Harvard Business School
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.